CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 748 enrolled
Drug / intervention
Olumacostat Glasaretil Gel, 5.0%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03127956
NCT03127956Phase 3Completed
CompareCT.gov

An Open-Label Study Assessing Long-Term Safety of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

Dermira, Inc.·interventional·Posted Apr 25, 2017·Updated Jul 20, 2021

In Brief

A Phase 3 clinical trial evaluating Olumacostat Glasaretil Gel, 5.0% for Acne Vulgaris. Completed, enrolled 748 participants across 94 sites in 3 countries.

Detailed Summary

The objective of this study is to assess the long-term safety of Olumacostat Glasaretil gel, 5.0% in patients with acne vulgaris

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesAustralia, Canada, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 25, 2017
Enrollment StartMar 21, 2017
Primary CompletionApr 27, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.2 years ago

Interventions

Olumacostat Glasaretil Gel, 5.0%drug

Gel containing Olumacostat Glasaretil